Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies

Traci C. Green; Rachel Serafinski; Seth A. Clark; Josiah D. Rich; Jeffrey Bratberg

doi:10.1056/NEJMc2208055

Back

Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies

Journal article

Peer reviewed

Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies

Traci C. Green, Rachel Serafinski, Seth A. Clark, Josiah D. Rich and Jeffrey Bratberg

The New England journal of medicine, Vol.388(2), pp.185-186

01/12/2023

DOI: https://doi.org/10.1056/NEJMc2208055

PMID: 36630629

Abstract

Addiction

Emergency Medicine

Emergency Medicine General

Health Care Delivery

Health Policy

Neurology

Neurosurgery

Neurosurgery General

Psychiatry

In a pilot trial of pharmacy-based buprenorphine induction in Rhode Island, retention was substantially higher in a pharmacy-based follow-up buprenorphine treatment program than in usual care.

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

19 Record Views

See more details

Details

Title: Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies
Creators: Traci C. Green - Rhode Island Hospital
Rachel Serafinski - Rhode Island Hospital
Seth A. Clark - Rhode Island Hospital
Josiah D. Rich - Rhode Island Hospital
Jeffrey Bratberg - University of Rhode Island
Publication Details: The New England journal of medicine, Vol.388(2), pp.185-186
Publisher: Massachusetts Medical Society
Identifiers: 9924193627601921
Academic Unit: Heller School for Social Policy and Management
Language: English
Resource Type: Journal article

Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies

Abstract

UN Sustainable Development Goals (SDGs)

Metrics

Details

Brandeis University Social media